New T-Cell Therapies for Brain Metastasis, CD133 in the Driver's Seat.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38038689.
- Also identified by DOI 10.1158/1078-0432.CCR-23-3051 and PMC identifier 10842869.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized cancer therapy for some advanced cancers, but success is predicated on identifying the correct cell surface target. In a recent article, the authors leveraged the cancer stem cell surface antigen CD133 to develop a CAR-T therapy for brain metastasis. See related article by Kieliszek et al., p. 554.
Medical subject headings
- Immunotherapy, Adoptive
- Brain Neoplasms